PremiumPre-EarningsIs AMPH a Buy, Before Earnings? Palantir upgraded, Nio downgraded: Wall Street’s top analyst calls Amphastar downgraded to Neutral from Overweight at Piper Sandler PremiumPre-EarningsAMPH Earnings this Week: How Will it Perform? Amphastar price target lowered to $66 from $71 at Piper Sandler Amphastar Pharmaceuticals Inc (AMPH) Q2 Earnings Cheat Sheet PremiumThe FlyFTC expands patent listing challenges for drugs Amphastar Pharmaceuticals (NASDAQ:AMPH) Offers Savvy Value Investors a Window of Opportunity Amphastar initiated with an Overweight at JPMorgan 
